Abstract Fibrosis is a major cause of end-stage renal disease (ESRD), a progressive loss in renal function that occurs over a period of months or years, is characterized by a decreased capability of the kidneys to excrete waste products. There is no specific treatment unequivocally shown to slow the worsening of chronic kidney disease. Plasma levels of CCN2, a fibrogenic agent, is a predictor of ESRD and mortality in patients with type 1 diabetic nephropathy. CCN3 has been hypothesized to have antagonistic effects to CCN2 both in vitro and in vivo, including in cultured mesangial cells. In a recent study, van Roeyen and colleagues (Am J Pathol in press, 2012) showed that in vivo overexpression of CCN3 in a model of anti-Thy1.1-induced experimental glomerulonephritis resulted in decreased albuminuria, glomerulosclerosis and reduced cortical collagen type I accumulation. CCN3 enhanced angiogenesis yes suppressed mesangial cell proliferation. Thus CCN3 protein may represent a novel therapeutic approach to help repair glomerular endothelial damage and mesangioproliferative changes and hence prevent renal failure, glomerulosclerosis and tubulointerstitial fibrosis.
but not nephritic rats. Thus CCN3 had pro-angiogenic and anti-mesangioproliferative effects in experimental glomerulonephritis, both of which helped to preserve and reconstitute normal glomerular architecture.
CCN3 therefore represents a potentially novel therapeutic tool to help repair glomerular endothelial damage and mesangioproliferative changes. Further efforts need to be expended in evaluating whether CCN3 could be used as a biological agent to prevent or revert diabetes, for example, in humans. 
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